In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Humanigen (HGEN – Research Report). The company’s shares closed last Friday at $0.36.
According to TipRanks, Pantginis is an analyst with an average return of -17.8% and a 33.16% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and PDS Biotechnology.
Currently, the analyst consensus on Humanigen is a Hold with an average price target of $1.50.
See the top stocks recommended by analysts >>
HGEN market cap is currently $25.64M and has a P/E ratio of -0.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.
Read More on HGEN:
- H.C. Wainwright Sticks to Its Buy Rating for Savara (SVRA)
- H.C. Wainwright Keeps Their Buy Rating on Plus Therapeutics (PSTV)
- H.C. Wainwright Sticks to Its Buy Rating for Oncorus (ONCR)
- H.C. Wainwright Sticks to Their Buy Rating for Harpoon Therapeutics (HARP)
- H.C. Wainwright Keeps Their Buy Rating on Phasebio Pharmaceuticals (PHAS)
